Literature DB >> 6360636

Antimicrobial drugs used in the management of anaerobic infections in children.

I Brook.   

Abstract

Optimum antimicrobial therapy effective against anaerobes is required to rapidly resolve infections due to these organisms and to prevent serious complications. Selection of antimicrobial therapy should be based on clinical experience and presumptive evidence until culture and sensitivity tests are available. If an abscess should develop, surgical drainage (when possible) is of paramount importance. Antimicrobial therapy for anaerobic infections should usually be given for prolonged periods because of the tendency for relapse, and should include coverage for aerobic bacteria whenever they are present. Penicillin G remains the drug of choice for most anaerobic infections except those caused by beta-lactamase-producing Bacteroides spp. such as B. fragilis and B. melaninogenicus, and some strains of Fusobacterium varium, which can be resistant. Other antimicrobials which are available for treatment of anaerobic infections in paediatric patients, and are generally active against B. fragilis, are carbenicillin, ticarcillin, chloramphenicol, clindamycin and cefoxitin. Experience in the use of metronidazole suggests that it could be a very valuable antimicrobial agent in the treatment of anaerobic infections. Experience with synergistic antimicrobial combinations in the treatment of anaerobic infections is limited; only experimental data are available suggesting synergism between penicillin and aminoglycosides against some Bacteroides spp. beta-Lactamase-producing anaerobic bacteria may protect other penicillin-susceptible bacteria in mixed infections. This phenomenon may explain penicillin failure in eradicating mixed infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360636     DOI: 10.2165/00003495-198326060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  56 in total

1.  Anaerobic meningitis and bacteremia caused by Fusobacterium species.

Authors:  L R O'Grady; E D Ralph
Journal:  Am J Dis Child       Date:  1976-08

2.  Letter: Bacteroides infections.

Authors:  D A Leigh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

3.  [Metronidazole-spiramycin combination. In situ concentrations and synergism compared with the minimal inhibitory concentration of the buccal flora].

Authors:  J Laufer; H Mignon; D Videau
Journal:  Rev Stomatol Chir Maxillofac       Date:  1974 Jul-Aug

4.  Anaerobic infections. 1.

Authors:  S L Gorbach; J G Bartlett
Journal:  N Engl J Med       Date:  1974-05-23       Impact factor: 91.245

5.  Treatment of anaerobic infections with metronidazole.

Authors:  F P Tally; V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

6.  Bacteroides bacteremia. Experience in a hospital for neoplastic diseases.

Authors:  M F Kagnoff; D Armstrong; A Blevins
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

7.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

8.  In-vivo protection of group A beta-haemolytic streptococci from penicillin by beta-lactamase-producing Bacteroides species.

Authors:  I Brook; G Pazzaglia; J C Coolbaugh; R I Walker
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

9.  Anaerobic isolates in chronic recurrent suppurative otitis media. Treatment with carbenicillin alone and in combination with gentamicin.

Authors:  I Brook
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin.

Authors:  I Roy; V Bach; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

View more
  1 in total

1.  Recovery of aerobic and anaerobic bacteria from irradiated mice.

Authors:  I Brook; T J MacVittie; R I Walker
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.